Cytokinetics, Incorporated (NASDAQ:CYTK) CEO Robert I. Blum sold 5,000 shares of the business’s stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $14.59, for a total transaction of $72,950.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Shares of Cytokinetics, Incorporated (NASDAQ CYTK) traded up 2.64% on Wednesday, reaching $15.55. 322,627 shares of the company traded hands. The company’s market capitalization is $834.51 million. Cytokinetics, Incorporated has a one year low of $8.77 and a one year high of $17.20. The firm’s 50 day moving average is $13.92 and its 200 day moving average is $13.71.

Cytokinetics, (NASDAQ:CYTK) last released its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.60) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.57) by ($0.03). Cytokinetics, had a negative net margin of 16.00% and a negative return on equity of 14.15%. The business had revenue of $3.05 million during the quarter, compared to the consensus estimate of $5.28 million. Analysts expect that Cytokinetics, Incorporated will post ($2.46) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This news story was reported by American Banking News and is the property of of American Banking News. If you are reading this news story on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2017/10/04/insider-selling-cytokinetics-incorporated-cytk-ceo-sells-5000-shares-of-stock.html.

A number of institutional investors have recently added to or reduced their stakes in CYTK. Janus Henderson Group PLC bought a new position in Cytokinetics, in the second quarter valued at about $32,488,000. Vanguard Group Inc. grew its position in Cytokinetics, by 59.9% in the second quarter. Vanguard Group Inc. now owns 3,117,496 shares of the biopharmaceutical company’s stock valued at $37,721,000 after acquiring an additional 1,168,151 shares during the last quarter. State Street Corp grew its position in Cytokinetics, by 79.6% in the second quarter. State Street Corp now owns 1,674,335 shares of the biopharmaceutical company’s stock valued at $20,259,000 after acquiring an additional 741,909 shares during the last quarter. FMR LLC grew its position in Cytokinetics, by 8.8% in the first quarter. FMR LLC now owns 5,655,916 shares of the biopharmaceutical company’s stock valued at $72,679,000 after acquiring an additional 456,502 shares during the last quarter. Finally, Acadian Asset Management LLC grew its position in Cytokinetics, by 128.9% in the second quarter. Acadian Asset Management LLC now owns 766,263 shares of the biopharmaceutical company’s stock valued at $9,271,000 after acquiring an additional 431,457 shares during the last quarter. Hedge funds and other institutional investors own 71.51% of the company’s stock.

Several equities research analysts have recently commented on CYTK shares. Needham & Company LLC restated a “buy” rating and issued a $22.00 target price on shares of Cytokinetics, in a research note on Sunday, September 17th. Zacks Investment Research upgraded shares of Cytokinetics, from a “hold” rating to a “buy” rating and set a $14.00 price target on the stock in a research report on Tuesday, July 11th. Morgan Stanley started coverage on shares of Cytokinetics, in a research report on Monday, July 31st. They set an “overweight” rating and a $24.00 price target on the stock. ValuEngine upgraded shares of Cytokinetics, from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. Finally, Cowen and Company reiterated a “buy” rating and set a $19.00 price target on shares of Cytokinetics, in a research report on Friday, August 4th. Three analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $21.30.

About Cytokinetics,

Cytokinetics, Incorporated is a late-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions.

Insider Buying and Selling by Quarter for Cytokinetics, (NASDAQ:CYTK)

Receive News & Ratings for Cytokinetics Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.